The Effect of Conbercept Injection Through Different Routes for Neovascular Glaucoma

NCT03154892 | Completed

• 1 other identifier: Conbercept Injection
• Study Type: interventional
• Target: 30
• Locations: 1 country
• Sites: 1

Brief Summary

The neovascular glaucoma (NVG) is a refractory type of secondary glaucoma and often lead to frustrated treatment and blindness. It has been confirmed high levels of vascular endothelial growth factor (VEGF) in NVG. Conbercept is an anti-VEGF agent，its role in regression of other neovascular disorders such as wet-type age-related macular degeneration and diabetic retinopathy has been described. Investigators aim to evaluate the efficacy and safety of intracameral and intravitreal injection of conbercept for the treatment of NVG.

Conditions

Neovascular Glaucoma

Outcome Measures

Primary Outcomes (1)

• NVI/NVA

  Changes in extent of iris or angle neovascularization

  1 week and 1 month after operation

Secondary Outcomes (2)

• IOP

  1 week and 1 month after operation

• BCVA

  1 week and 1 month after operation

Study Arms (2)

Intracameral injection

EXPERIMENTAL

Intracameral injection of conbercept for the treatment of NVG

Procedure: Intracameral injection

Intravitreal injection

ACTIVE COMPARATOR

Intravitreal injection of conbercept for the treatment of NVG

Procedure: Intravitreal injection

Interventions

Intracameral injection PROCEDURE

Intracameral Conbercept injection for the treatment of NVG

Intracameral injection

Intravitreal injection PROCEDURE

Intravitreal Conbercept injection for the treatment of NVG

Intravitreal injection

Eligibility Criteria

• Age: 20 Years - 80 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Patients with a diagnosis of neovascular glaucoma (Stage 1-2-3)
• Individuals who are ages 20-80 years old; male or female of chinese
• Visual acuity of light perception or better in the study eye
• Willing and able to comply with clinic visits and study-related procedures
• Provide signed informed consent

You may not qualify if:

• Use of intraocular anti-VEGF agents in the study eye in the past 3 months.
• Active ocular or periocular infection in the study eye
• Uncontrolled Blood Pressure
• Thromboembolism
• Congestive Heart Failure
• Renal Failure
• History of myocardial infarction
• History of Stroke
• Pregnant or breast-feeding women
• Participation in another simultaneous medical investigator or trial

Sponsors & Collaborators

• Second Affiliated Hospital of Xi'an Jiaotong University: lead

Study Sites (1)

Department of Ophthalmology, Second affiliated hospital of Xian Jiaotong University

Xi'an, Shaanxi, 710004, China

Location

Related Publications (1)

• Bai L, Wang Y, Liu X, Zheng Y, Wang W, He N, Tariq F, Wang F, Zhang S. The Optimization of an Anti-VEGF Therapeutic Regimen for Neovascular Glaucoma. Front Med (Lausanne). 2022 Jan 10;8:766032. doi: 10.3389/fmed.2021.766032. eCollection 2021.

  PMID: 35083234 DERIVED

MeSH Terms

Conditions

Glaucoma, Neovascular

Interventions

Intracameral Injection; Intravitreal Injections

Condition Hierarchy (Ancestors)

Glaucoma; Ocular Hypertension; Eye Diseases

Intervention Hierarchy (Ancestors)

Injections, Intraocular; Injections; Drug Administration Routes; Drug Therapy; Therapeutics

Study Officials

• Ling Bai, MD,PhD

  Second affiliated hospital of Xian Jiaotong University

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: May 7, 2017
• First Posted: May 16, 2017
• Study Start: April 1, 2017
• Primary Completion: December 31, 2017
• Study Completion: December 31, 2017
• Last Updated: May 23, 2018

Record last verified: 2018-05

Data Sharing

• IPD Sharing: Will not share

Locations

CN (1)